VANCOUVER, British Columbia, June 03, 2024 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV:AVCR) (the "Company" or "Avricore") reports on results for the first three months of 2024, the first period of net profitability for the Company.   The Company realized a comprehensive income of $168,537 for the three months ended March 31, 2024 (2023 - loss $191,512) and a net increase in cash of $307,470, demonstrating the Company's commitment to growth while managing operational efficiencies. "HealthTab™'s end-to-end offering is making the typically complex point-of-care programs in pharmacy easy," said Hector Bremner, CEO of Avricore. "With chronic disease prescribing already coming to some Canadian provinces in early 2025, we're excited to help more pharmacists deliver timely care to patients who need it." First quarter 2024 profitable The Company incurred a comprehensive income of $168,537 for the three months ended March 31, 2024 (2023 - loss $191,512) and a net increase in cash of $307,470. In the period ended March 31, 2024 revenue increased by 79% year over year to $1,124,307 and gross profit increased by 130% to $484,791.  Gross margin for the period was 43% (2023- 33%) outperforming the Company's target margin of 30%.   3 mo ended March 31   2024 2023       Revenue $1,124,307 $629,241       % Change - year over year 79%   Gross profit $484,791 $210,681 % Change - year over year 130%         Comprehensive Income $168,537 $(191,512)             The following table highlights selected financial data for each of the eight most recent quarters. Quarter Ended Mar 2024 Dec 2023